Relaxin Treatment in an Ang-II-Based Transgenic Preeclamptic-Rat Model
Standard
Relaxin Treatment in an Ang-II-Based Transgenic Preeclamptic-Rat Model. / Haase, Nadine; Golic, Michaela; Herse, Florian; Rugor, Julianna; Linz, Dominik; Solano, Maria Emilia; Müller, Dominik N; Dechend, Ralf.
in: PLOS ONE, Jahrgang 11, Nr. 3, 2016, S. e0150743.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Relaxin Treatment in an Ang-II-Based Transgenic Preeclamptic-Rat Model
AU - Haase, Nadine
AU - Golic, Michaela
AU - Herse, Florian
AU - Rugor, Julianna
AU - Linz, Dominik
AU - Solano, Maria Emilia
AU - Müller, Dominik N
AU - Dechend, Ralf
PY - 2016
Y1 - 2016
N2 - Relaxin is a peptide related to pregnancy that induces nitric oxide-related and gelatinase-related effects, allowing vasodilation and pregnancy-related adjustments permitting parturition to occur. Relaxin controls the hemodynamic and renovascular adaptive changes that occur during pregnancy. Interest has evolved regarding relaxin and a therapeutic principle in preeclampsia and heart failure. Preeclampsia is a pregnancy disorder, featuring hypertension, proteinuria and placental anomalies. We investigated relaxin in an established transgenic rat model of preeclampsia, where the phenotype is induced by angiotensin (Ang)-II production in mid pregnancy. We gave recombinant relaxin to preeclamtic rats at day 9 of gestation. Hypertension and proteinuria was not ameliorated after relaxin administration. Intrauterine growth retardation of the fetus was unaltered by relaxin. Heart-rate responses and relaxin levels documented drug effects. In this Ang-II-based model of preeclampsia, we could not show a salubrious effect on preeclampsia.
AB - Relaxin is a peptide related to pregnancy that induces nitric oxide-related and gelatinase-related effects, allowing vasodilation and pregnancy-related adjustments permitting parturition to occur. Relaxin controls the hemodynamic and renovascular adaptive changes that occur during pregnancy. Interest has evolved regarding relaxin and a therapeutic principle in preeclampsia and heart failure. Preeclampsia is a pregnancy disorder, featuring hypertension, proteinuria and placental anomalies. We investigated relaxin in an established transgenic rat model of preeclampsia, where the phenotype is induced by angiotensin (Ang)-II production in mid pregnancy. We gave recombinant relaxin to preeclamtic rats at day 9 of gestation. Hypertension and proteinuria was not ameliorated after relaxin administration. Intrauterine growth retardation of the fetus was unaltered by relaxin. Heart-rate responses and relaxin levels documented drug effects. In this Ang-II-based model of preeclampsia, we could not show a salubrious effect on preeclampsia.
KW - Angiotensins
KW - Animals
KW - Disease Models, Animal
KW - Female
KW - Fetal Growth Retardation
KW - Pre-Eclampsia
KW - Pregnancy
KW - Rats
KW - Rats, Transgenic
KW - Relaxin
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.1371/journal.pone.0150743
DO - 10.1371/journal.pone.0150743
M3 - SCORING: Journal article
C2 - 26963382
VL - 11
SP - e0150743
JO - PLOS ONE
JF - PLOS ONE
SN - 1932-6203
IS - 3
ER -